Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27742860 | 0.76 | L3MBTL1 (0.42) | HSD11B1CYP2C9EPHX2L3MBTL1HSD17B10 | |
| SCHEMBL26229896 | 0.74 | HSD11B1 (0.40) | HSD11B1CYP2C9EPHX2L3MBTL1HSD17B10 | |
| SCHEMBL28913743 | 0.71 | HSD11B1 (0.38) | HSD11B1CYP2C9EPHX2L3MBTL1HSD17B10 | |
| SCHEMBL8076053 | 0.71 | HSD11B1 (0.38) | HSD11B1CYP2C9EPHX2L3MBTL1HSD17B10 | |
| SCHEMBL5401965 | 0.71 | HSD11B1 (0.48) | HSD11B1CYP2C9EPHX2L3MBTL1HSD17B10 | |
| Adamantane SCHEMBL20335270 | 0.71 | TSHR (0.62) | HSD11B1 | |
| SCHEMBL161392 | 0.70 | HSD11B1 (0.44) | HSD11B1CYP2C9EPHX2L3MBTL1HSD17B10 | |
| SCHEMBL16698251 | 0.69 | HSD11B1 (0.48) | HSD11B1CYP2C9L3MBTL1HSD17B10 | |
| SCHEMBL2181379 | 0.69 | HSD11B1 (0.46) | HSD11B1CYP2C9EPHX2L3MBTL1HSD17B10 | |
| SCHEMBL19859959 | 0.69 | HSD11B1 (0.48) | HSD11B1CYP2C9L3MBTL1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187438-B2 | Derivatives of benzothiazines, preparation thereof and application thereof as drugs | PIERRE FABRE MEDICAMENT (FR) | 2015-11-17 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| EP-2403840-B1 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS | PF MEDICAMENT (FR) | 2014-05-14 | — | — | EP | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| EP-2403840-A1 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS | Pierre Fabre Médicament (FR) | 2012-01-11 | — | — | EP | disclosed |
| US-20110319326-A1 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 2011-12-29 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| WO-2010100139-A1 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 2010-09-10 | — | — | WO | disclosed |
| EP-1836161-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-7119156-B2 | Resist resin | KABUSHIKI KAISHA TOSHIBA (JP) | 2006-10-10 | — | — | US | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
| WO-2006085149-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | WO | disclosed |
| EP-1206474-B1 | SULFONYLPHENYLPYRAZOLE COMPOUNDS USEFUL AS COX-2 INHIBITORS | ABBOTT LAB (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6472416-B1 | Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors | ABBOTT LABORATORIES | 2002-10-29 | — | — | US | disclosed |
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | ENG WAI-SI (US) | 2002-06-13 | — | — | US | disclosed |
| EP-1206474-A1 | SULFONYLPHENYLPYRAZOLE COMPOUNDS USEFUL AS COX-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001022963-A1 | METHOD OF PREVENTING OSTEOPOROSIS | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001016138-A1 | SULFONYLPHENYLPYRAZOLE COMPOUNDS USEFUL AS COX-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | GGT1, FNTA, GGPS1 | HSD11B1 251/4885CYP2C9 2217/4885EPHX2 732/4885 |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | HSD11B1 2010/4885CYP2C9 3354/4885EPHX2 2234/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | HSD11B1 936/4885CYP2C9 2993/4885EPHX2 678/4885 |
| US-20110319326-A1 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS | HSD11B1, CYP11B1, HSD17B11 | HSD11B1 1/4885CYP2C9 89/4885EPHX2 665/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | HSD11B1 705/4885CYP2C9 2005/4885EPHX2 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.